Korea Joongang Daily

Home > >

Medytox, Daewoong benefit as Botox deal nullifies ITC ban

After emerging victorious in a protracted trade secrets dispute last year, Medytox has received billions of dollars in license fees and royalty fees and bought a stake in the U.S. botulinum toxin maker Evolus, becoming its second largest stakeholder.

2021-02-22

U.S. ITC ends 'Botox brawl' in Medytox's favor, but reduces penalty

After a two-year investigation, the U.S. International Trade Commission has made a final determination in favor of Medytox in its high-profile “Botox brawl” with Daewoong Pharmaceutical.

2020-12-17

Hugel begins exporting its Botox to China

Biopharmaceutical company Hugel has started exporting its botulinum toxin to China on Wednesday — the first among Korea’s “Botox” manufacturers to do so.

2020-12-09

What’s Popular Now